DuLac Farmaceutici is moving forward with U.S. retail expansion after participating in the 2026 ECRM Vitamin, Weight Management & Sports Nutrition Session, held September 14-17 in Palm Beach Gardens, Florida. The Italian pharmaceutical company is now following up with prospective retail and distribution partners to explore product assortment and distribution opportunities in the United States. This step marks another phase in DuLac's effort to build a broader U.S. retail presence beyond its established Amazon business.
The ECRM event provided a platform for DuLac to discuss its Italian-developed portfolio with buyers across health, specialty, food, drug, and mass retail channels. The company's portfolio includes its high-concentration Arnica Gel 98% range, topical leg-care products, and the Dinaven and Diosmin lines. These products reflect DuLac's Italian manufacturing expertise, botanical formulation capabilities, and more than 30 years of pharmaceutical industry experience.
DuLac enters these discussions with products already available to U.S. consumers through its Amazon storefront and OneLavi. Customer feedback offers an additional reference point for prospective partners: the company's Arnica Gel 98% listing on Amazon.com has an average customer rating of 4.5 out of 5 stars, demonstrating consumer traction that partners can evaluate.
Gabriele Bollani, Founder and CEO of DuLac Farmaceutici, emphasized the company's collaborative approach: "Our priority following ECRM is to work with prospective partners to identify the DuLac products that best fit their customers and channels. We want to build lasting relationships by combining our Italian formulation and manufacturing expertise with a clear understanding of each partner's commercial needs."
During the meetings, DuLac introduced buyers to the research and manufacturing approach behind its products, including its proprietary Arnica Montana Arricchita™ project and its work with botanical ingredients and advanced extraction technologies. The company's European pharmacy heritage and Italian production provide the foundation for its portfolio. Follow-up discussions will focus on the products relevant to each prospective partner, their positioning, and the requirements for a potential launch.
Following ECRM, DuLac is continuing discussions with prospective partners to assess product assortment, channel fit, and distribution opportunities, while building on its existing U.S. e-commerce presence. The company's long-term objective is to establish DuLac as a nationally recognized U.S. brand across multiple channels, combining its European pharmacy heritage and Italian manufacturing with the consumer traction it has already established in the American market.
This expansion matters because it signals growing opportunities for U.S. retailers to offer differentiated, high-quality Italian dermo-cosmetic products. For consumers, it means increased access to products backed by pharmaceutical-grade manufacturing and botanical innovation. For the industry, DuLac's move highlights the value of international partnerships in meeting diverse consumer needs and underscores the potential for European brands to succeed in the competitive U.S. market.
